Publications

Endogenous endophthalmitis is a serious vision-threatening condition commonly associated with immunosuppression and is invariably linked to a systemic focus. Rituximab infusion is one of the treatment options for refractory Myasthenia Gravis but can become a double-edged sword, increasing susceptibility to serious infections. This study reports the occurrence and management of Endogenous endophthalmitis in two patients after rituximab infusion given for refractory Myasthenia Gravis. Endogenous endophthalmitis post Rituximab has not been reported.